Abstract:Over 50% of patients who take statins are still at risk of developing atherosclerotic cardiovascular disease (ASCVD) and do not achieve their goal LDL-C levels. This residual risk is largely dependent on triglyceride-rich lipoproteins (TRL) and their remnants. In essence, remnant cholesterol-rich chylomicron (CM) and very-low-density lipoprotein (VLDL) particles play a role in atherogenesis. These remnants increase when lipoprotein lipase (LPL) activity is inhibited. ApoCIII has been thoroughly studied as a chief inhibitor and therapeutic options to curb its effect are available. On top of apoCIII regulation of LPL activity, there is a more precise control of LPL in various tissues, which makes it easier to physiologically divide the TRL burden according to the body's requirements. In general, oxidative tissues such as skeletal and cardiac muscle preferentially take up lipids during fasting. Conversely, LPL activity in adipocytes increases significantly after feeding, while its activity in oxidative tissues decreases concurrently. This perspective addresses the recent improvements in our understanding of circadian LPL regulations and their therapeutic implications. Three major tissue-specific lipolysis regulators have been identified: ANGPTL3, ANGPTL4, and ANGPTL8. Briefly, during the postprandial phase, liver ANGPTL8 acts on ANGPTL3 (which is released continuously from the liver) to inhibit LPL in the heart and muscle through an endocrine mechanism. On the other hand, when fasting, ANGPTL4, which is released by adipocytes, inhibits lipoprotein lipase in adipose tissue in a paracrine manner. ANGPTL3 inhibitors may play a therapeutic role in the treatment of hypertriglyceridemia. Several approaches are under development. We look forward to future studies to clarify (a) the nature of hormonal and nutritional factors that determine ANGPTL3, 4, and 8 activities, along with what long-term impacts may be expected if their regulation is impaired pharmacologically; (b) the understanding of the quantitative hierarchy and interaction of the regulatory actions of apoCIII, apoAV, and ANGPTL on LPL activity; (c) strategies for the safe and proper treatment of postprandial lipemia; and (d) the effect of fructose restriction on ANGPTL3, ANGPTL4, and ANGPTL8.

Upregulating APOAV Expression by Statins Via PPAR-α Activated Pathway Possibly Contributes to Their Triglyceride-Lowering Effect

Effects of Atorvastatin on Bile Acid Metabolism in High-Fat Diet-Fed ApoE-/- Mice

Oat Avenanthramide B Alleviates High-Fat Diet-Induced Obesity Via Regulating Fatty Acid Metabolism Involved in Gut Bacteria and Fungi Remodeling

Effect Of Mir-34a In Regulating Steatosis By Targeting Ppar Alpha Expression In Nonalcoholic Fatty Liver Disease

Effect of miR-34a in regulating steatosis by targeting PPARα expression in nonalcoholic fatty liver disease

Effects and mechanisms of apolipoprotein A-V on the regulation of lipid accumulation in cardiomyocytes

PRAVASTATIN ATTENUATES INTERFERON‐γ ACTION VIA MODULATION OF STAT1 TO PREVENT AORTIC ATHEROSCLEROSIS IN APOLIPOPROTEIN E‐KNOCKOUT MICE

The role of PPARs in atherosclerosis

Modulation Effect of Peroxisome Proliferator-Activated Receptor Agonists on Lipid Droplet Proteins in Liver

Enhancing PPARγ by HDAC Inhibition Reduces Foam Cell Formation and Atherosclerosis in ApoE Deficient Mice

[Role of Adiponectin and Its Receptors in Anti-Atherosclerotic Effects of Pioglitazone on ApoE Knocked out Mice].

Role of Apolipoprotein A1 in PPAR Signaling Pathway for Nonalcoholic Fatty Liver Disease

r20 (S)-protopanaxatriol improves atherosclerosis by inhibiting low-density lipoprotein receptor degradation in ApoE KO mice

Effect of Atorvastatin on the Expression of Apolipoprotein M

Aspirin increases apolipoprotein-A-I-mediated cholesterol efflux via enhancing expression of ATP-binding cassette transporter A1.

Angiopoietin-like Proteins and Lipoprotein Lipase: The Waltz Partners That Govern Triglyceride-Rich Lipoprotein Metabolism? Impact on Atherogenesis, Dietary Interventions, and Emerging Therapies

Activation of peroxisome proliferator-activated receptor γ inhibits osteoprotegerin gene expression in human aortic smooth muscle cells

Palmitic Acid Suppresses Apolipoprotein M Gene Expression Via the Pathway of PPARβ/δ in HepG2 Cells

Reductions in remnant cholesterol and VLDL cholesterol through inhibition of ANGPTL3 protein synthesis: an analysis from the TRANSLATE-TIMI 70 trial

Lovastatin reduces nuclear factor kappaB activation induced by C-reactive protein in human vascular endothelial cells.

Apolipoprotein A4 Restricts Diet-Induced Hepatic Steatosis Via SREBF1-Mediated Lipogenesis and Enhances IRS-PI3K-Akt Signaling.